Advanced Biomed Inc. (ADVB)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 54/100 (HIGH), 5.4 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 1.56% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Advanced Biomed Inc. Announces 1 for 20 Share Consolidation
- Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
- Advanced Biomed sells Hong Kong subsidiary for $23,000
- Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Systemic Therapy for Advanced Hepatocellular Carcinoma with Impaired Liver Function: Navigating the Evidence Gap. — Cancers (Basel) 2026 Sep 20 PMID 42795014
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Advanced Biomed Inc..
Full ADVB Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.